Skip to main content

Prevention of Infections With Bordetella Pertussis

3
Pipeline Programs
3
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
3
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

ViiV Healthcare
ViiV HealthcareNC - Durham
1 program
1
BoostrixPhase 41 trial
Active Trials
NCT02555540Completed240Est. Dec 2016
Sandoz
SandozAustria - Kundl
1 program
1
BoostrixPhase 4
deCode Genetics
deCode GeneticsIceland - Reykjavik
1 program
1
BoostrixPhase 4

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
ViiV HealthcareBoostrix

Clinical Trials (1)

Total enrollment: 240 patients across 1 trials

Placebo Controlled Study to Generate Data Characterising Safety Parameters and Immune Responses

Start: Aug 2015Est. completion: Dec 2016240 patients
Phase 4Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.